Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, especially for patients who may not have easy access to PSMA PET scans.

An AI-driven tool enhances stereotactic radiosurgery for small brain metastases by predicting local failure risks, optimizing radiation dosing, and personalizing MRI follow-ups.

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

Panelist discusses how there are many significant attributes of the bispecific antibody, which has broader applicability and can be used in widespread community centers. There are more community ...

During a Case-Based Roundtable® event, Andrew Kuykendall, MD, discussed treatment for a 68-year-old patient with intermediate ...

Ryan Motte, PharmD, CSP, reviewed the global cancer burden among men and its projected trajectory to 2050, highlighting the ...

The advent of cellular therapies, such as chimeric antigen receptor T-cell therapy, has revolutionized the field of ...

Joseph Greer, PhD, discussed a study evaluating in-person vs telehealth modalities of early integrated palliative care for ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Dr. Joshua Sabari discusses the impact that identification of common and rare actionable alterations has had on personalized ...